JPMorgan thinks investors should flock to biotechnology company Beam Therapeutics , which the firm says stands to benefit from increased market share and a strong gene therapy pipeline.
"We see BEAM outperforming our coverage over the mid-term, with current levels being an attractive entry point," the analyst said.
The stock is down more than 4% so far this year, and has lost more than 42% over the past 12 months.
BEAM 1Y mountain Beam stock.
He added that BEAM-302 is "uniquely positioned" as a one-time genetic medicine for AATD, particularly given its success in preclinical trials.
Persons:
Eric Joseph, Joseph
Organizations:
Beam Therapeutics, TAM
Locations:
U.S, 1H24